GSK PLC Sponsored ADR (NYSE:GSK) Receives Consensus Rating of “Hold” from Analysts

GSK PLC Sponsored ADR (NYSE:GSK) has been given an average rating of “Hold” by the ten analysts that are presently covering the company, MarketBeat reports. Three investment analysts have rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $53.00.

A number of research firms recently issued reports on GSK. Weiss Ratings cut shares of GSK from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday. Royal Bank Of Canada reissued an “outperform” rating on shares of GSK in a research note on Tuesday, June 9th. Barclays restated an “underweight” rating on shares of GSK in a report on Friday, February 20th. Finally, Wall Street Zen lowered GSK from a “buy” rating to a “hold” rating in a report on Saturday, May 30th.

GSK Price Performance

GSK stock opened at $52.23 on Tuesday. The company’s fifty day moving average price is $53.07 and its 200 day moving average price is $52.75. GSK has a 1 year low of $35.45 and a 1 year high of $61.69. The stock has a market capitalization of $105.77 billion, a P/E ratio of 13.57, a P/E/G ratio of 2.74 and a beta of 0.36. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.52 and a current ratio of 0.79.

GSK Cuts Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 9th. Shareholders of record on Friday, May 15th will be issued a $0.44 dividend. The ex-dividend date is Friday, May 15th. This represents a $1.76 dividend on an annualized basis and a yield of 3.4%. GSK’s dividend payout ratio (DPR) is presently 47.01%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Parallel Advisors LLC lifted its holdings in GSK by 17.5% in the 1st quarter. Parallel Advisors LLC now owns 9,424 shares of the pharmaceutical company’s stock valued at $520,000 after purchasing an additional 1,405 shares in the last quarter. Arkadios Wealth Advisors lifted its holdings in GSK by 0.6% in the 1st quarter. Arkadios Wealth Advisors now owns 108,026 shares of the pharmaceutical company’s stock valued at $5,962,000 after purchasing an additional 647 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in GSK by 67.6% in the 1st quarter. EverSource Wealth Advisors LLC now owns 6,092 shares of the pharmaceutical company’s stock valued at $336,000 after purchasing an additional 2,457 shares in the last quarter. Dorsey Wright & Associates purchased a new position in GSK in the 1st quarter valued at $2,522,000. Finally, Citizens National Bank Trust Department lifted its holdings in GSK by 14.7% in the 1st quarter. Citizens National Bank Trust Department now owns 3,122 shares of the pharmaceutical company’s stock valued at $172,000 after purchasing an additional 400 shares in the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Company Profile

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.